Apellis Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Cash & Equivalents	479.17	411.29	351.19	551.8	640.19	565.78
Short-Term Investments	1.06	4.85	4.35	6.51	61.04	311.87
Cash & Short-Term Investments	480.23	416.14	355.54	558.31	701.23	877.65
Cash Growth	18.96%	17.04%	-36.32%	-20.38%	-20.10%	149.34%
Accounts Receivable	354.64	271.72	224.5	29.17	80.1	25
Other Receivables	-	-	-	8.71	-	-
Receivables	354.64	271.72	224.5	37.88	80.1	25
Inventory	123.79	82.48	162.66	99.7	24	-
Prepaid Expenses	10.43	9.51	8.59	7.18	5.17	3.4
Restricted Cash	1.43	1.32	1.11	1.27	1.56	1.27
Other Current Assets	20.16	7.78	13.93	15.18	11.98	9.88
Total Current Assets	990.68	788.95	766.33	719.52	824.05	917.19
Property, Plant & Equipment	21.65	19.04	21.09	24.9	26.08	24.52
Long-Term Accounts Receivable	-	-	-	15	30	18
Other Long-Term Assets	46.4	77.06	1.31	0.8	1.64	0.86
Total Assets	1,059	885.05	788.73	760.22	881.77	960.57
Accounts Payable	38.6	38.57	37.52	37.34	16.91	8.48
Accrued Expenses	140.32	140.18	127.81	95.14	103.24	111.94
Current Portion of Long-Term Debt	93.58	-	-	-	-	-
Current Portion of Leases	7.02	6.75	6.44	5.63	4.12	3.69
Other Current Liabilities	-	-	75.83	29.5	7.58	4.23
Total Current Liabilities	279.53	185.51	247.59	167.61	131.85	128.33
Long-Term Debt	361.09	452.83	93.03	92.74	189.02	358.83
Long-Term Leases	13.68	10.2	11.45	14.35	17.08	15.22
Other Long-Term Liabilities	3.26	7.97	242.13	315.65	345.15	253.64
Total Liabilities	657.56	656.51	594.21	590.35	683.1	756.01
Common Stock	0.01	0.01	0.01	0.01	0.01	0.01
Additional Paid-In Capital	3,358	3,267	3,036	2,480	1,857	1,131
Retained Earnings	-2,954	-3,035	-2,837	-2,309	-1,657	-926.35
Comprehensive Income & Other	-2.4	-3.31	-3.54	-0.88	-2.09	-0.12
Total Common Equity	401.17	228.54	194.52	169.87	198.66	204.56
Shareholders' Equity	401.17	228.54	194.52	169.87	198.66	204.56
Total Liabilities & Equity	1,059	885.05	788.73	760.22	881.77	960.57
Total Debt	475.37	469.78	110.93	112.71	210.22	377.73
Net Cash (Debt)	4.86	-53.65	244.61	445.59	491.01	499.92
Net Cash Growth	-	-	-45.10%	-9.25%	-1.78%	156.43%
Net Cash Per Share	0.04	-0.43	2.06	4.20	5.82	6.65
Filing Date Shares Outstanding	126.53	125.52	120.58	111.29	97.73	80.38
Total Common Shares Outstanding	126.5	124.5	119.56	110.77	97.52	76.13
Working Capital	711.15	603.45	518.74	551.91	692.2	788.87
Book Value Per Share	3.17	1.84	1.63	1.53	2.04	2.69
Tangible Book Value	401.17	228.54	194.52	169.87	198.66	204.56
Tangible Book Value Per Share	3.17	1.84	1.63	1.53	2.04	2.69

Source: S&P Global Market Intelligence. Standard template. Financial Sources.